Dallas, Texas – September 09, 2014

Total Clinical Trial Management (TCTM) is a full service CRO created on the founding principle that relationships between research sites and the CRO is a critical element in ensuring successful study completion. TCTM’s proprietary TotalTouch Site Advantage process has proven to dramatically increase study timelines and deliver results.

The Phase 3 program used a once daily topical patch in the treatment of acute low back pain versus placebo. MEDRx Co., Ltd US subsidiary, IL Pharma and TCTM’s planned enrollment projections were 224 patients within 6 months at 10 research site locations. The study ultimately completed 5 weeks ahead of the aggressive timeline with 232 patients enrolled in 5 months at 7 sites. President and CEO of IL Pharma, Yuji Kuwabara stated “We attribute much of the success of the program to the unique approach that TCTM took in collaborating with the research sites.”…

Read the entire release at PRWeb
Click here to download in PDF format